Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $38.5 million.

  • Iovance Biotherapeutics' Cost of Revenue rose 2207.94% to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $213.4 million, marking a year-over-year increase of 18642.1%. This contributed to the annual value of $124.0 million for FY2024, which is 105290.56% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Cost of Revenue is $38.5 million, which was up 2207.94% from $56.7 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Cost of Revenue ranged from a high of $68.5 million in Q4 2024 and a low of $2.0 million during Q2 2023
  • Its 3-year average for Cost of Revenue is $29.4 million, with a median of $31.4 million in 2024.
  • Per our database at Business Quant, Iovance Biotherapeutics' Cost of Revenue surged by 147012.6% in 2024 and then surged by 2207.94% in 2025.
  • Iovance Biotherapeutics' Cost of Revenue (Quarter) stood at $4.4 million in 2023, then surged by 1470.13% to $68.5 million in 2024, then plummeted by 43.86% to $38.5 million in 2025.
  • Its Cost of Revenue stands at $38.5 million for Q3 2025, versus $56.7 million for Q2 2025 and $49.7 million for Q1 2025.